JC07 Rec'd PCT/PTO 21 APR ZUUJI

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE of the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

6 + 25

Refs.

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/519,121 Filing Date September 15, 2003 First Named Inventor Marc K. HELLERSTEIN Art Unit **Not Yet Assigned** Examiner Name **Not Yet Assigned** Attorney Docket Number 416272003900

ENCLOSURES (Check all that apply)							
Fee Trans	mittal	Drawing(s)	After Allowance Communication to Group				
Fee	Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences				
Amendment/Reply		Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)				
After	Final	Petition to Convert to a Provisional Application	Proprietary Information				
Affid	avits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address	Status Letter				
Extension	of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):				
Express Al	bandonment Request	Request for Refund	1. One Copy of each 25 Cited References				
Information Disclosure Statement w/ Form PTO/SB/08a/b (5 pages)		CD, Number of CD(s)	2. Return Receipt Postcard				
Certified C Document	opy of Priority (s)						
	to Missing Parts/ Application	Remarks					
	oonse to Missing Parts						
Ll unde	r 37 CFR 1.52 or 1.53						
	SIGNATI	JRE OF APPLICANT, ATTORNEY, OF	RAGENT				
Firm or Individual name	Michael R. Ward - Reg. No. 38 651						
Signature	Michael	. RWord					
Date	April /8 , 2005						

hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date	
shown below.	
Dated: April 19, 2005 Signature: Signature: (Leah Kjellen)	
Dated: April / , 2005 Signature: (Leah Kjellen)	



Patent Docket No. 416272003900 B02-077

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Marc K. HELLERSTEIN

Serial No.: 10/519,121

Filing Date: September 15, 2003

For: METHODS FOR MEASURING RATES

OF REVERSE CHOLESTEROL

TRANSPORT IN VIVO, AS AN INDEX

OF ANTI-ATHEROGENESIS

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO/SB/08a/b. Copies of foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

	This Supplemental Information Disclosure Statement is submitted:
	With the application; accordingly, no fee or separate requirements are required.
	Before the mailing of a first Office Action after the filing of a Request for Continued
	Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97
	(e)(1) has been provided.
\boxtimes	Within three months of the application filing date or before mailing of a first Office
	Action on the merits; accordingly, no fee or separate requirements are required.
	However, if applicable, a certification under 37 C.F.R. § 1.97 (e)(1) has been provided.
	After receipt of a first Office Action on the merits but before mailing of a final Office Action
	or Notice of Allowance.
	A fee is required. A check in the amount of is enclosed.
	A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to
	this submission in duplicate.
	A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee is
	believed to be due.
	After mailing of a final Office Action or Notice of Allowance, but before payment of the
	issue fee.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
	amount of is enclosed.
	A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
	form (PTO/SB/17 is attached to this submission in duplicate.)
	Applicant would appreciate the Examiner initialing and returning the Form

PTO/SB/08a/b, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. **416272003900**.

Dated: April /8, 2005

Application No. 10/519,121

Supplemental Information Disclosure Statement

Respectfully submitted,

By Wichael R. Ward

Registration No.: 38,651

MORRISON & FOERSTER LLP

425 Market Street

San Francisco, California 94105-2482

Telephone: (415) 268-6237 Facsimile: (415) 268-7522



Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number 10/519,121				
Filing Date	September 15, 2003			
First Named Inventor	Marc K. HELLERSTEIN			
Art Unit	Not Yet Assigned			
Examiner Name Not Yet Assigned				
Attorney Docket Number	416272003900			

			U.S. PATENT DOCUM	ENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant
Initials*	No.1		Applicant of Cited Document	Figures Appear	
	1.	US-4,332,784	06-01-1982	Smith et al.	
	2.	US-5,439,803	08-08-1995	Ross et al.	
	3.	US-6,653,076	11-25-2003	Franza, Jr. et al.	
	4.	US-2003/0148533	08-07-2003	Malloy et al.	
	5.	US-2003/0180710	09-25-2003	Lee et al.	
	6.	US-2003/0180800	09-25-2003	Lee et al.	
	7.	US-2004/0091943	05-13-2004	Schneider	
	8.	US-2004/0152994	08-05-2004	Meier-Augenstein	
	9.	US-2004/0253647	12-16-2004	Mathews et al.	
	10.	US-10/523,250	FD 01-26-2005	Hellerstein	
	11.	US-10/526,860	FD 09-04-2003	Hellerstein	
	12.	US-10/872,280	FD 06-17-2004	Hellerstein	
	13.	US-11/064,197	FD 02-22-2005	Hellerstein	·
	14.	US-11/078,083	FD 03-11-2005	Hellerstein	

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages		
Initials*	No. ¹	Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		Applicant of Cited Document	or Relevant Figures Appear	T ⁶	
	15.	WO-90/11371	10-04-1990	Anticancer, Inc.			
	16.	WO-93/25705	12-23-1993	Barranco			
	17.	WO-03/061479-A1	07/31/2003	Hellerstein			
	18.	WO-03/068919-A2	08/21/2003	Hellerstein			
	19.	WO-03/087314-A2	10/23/2003	Hellerstein			
	20.	WO-04/003493-A2	01/08/2004	Hellerstein			
	21.	WO-04/011426-A2	02/05/2004	Hellerstein			
	22.	WO-04/021863-A2	03/18/2004	Hellerstein			
	23.	WO-04/024941-A2	03/25/2004	Hellerstein			
	24.	WO-04/025270-A2	03/25/2004	Hellerstein			
	25.	WO-04/042360-A2	05/21/2004	Hellerstein			
	26.	WO-05/009597-A2	02/03/2005	Hellerstein			
	27.	WO-05/015155-A2	02/17/2005	Hellerstein			

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date	
Signature	 Considered	
(4040047	 	

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/519,121	
IN	IFORMATION	1 DI	SCLOSURE	Filing Date	September 15, 2003	
S	STATEMENT BY APPLICANT			First Named Inventor	Marc K. HELLERSTEIN	
(Use as many sheets as necessary)				Art Unit	Not Yet Assigned	
			necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	416272003900	

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	28.	International Search Report mailed on August 20, 2004, for PCT application no. PCT/US03/10554 filed on April 4, 2003, 4 pages				
	29.	International Search Report mailed July 8, 2004, for PCT patent application no. PCT/US03/27623 filed on September 4, 2003, 4 pages				
	30.	International Search Report mailed on March 25, 2005, for PCT application no. PCT/US04/39722 filed on November 24, 2004, 3 pages				
	31.	International Search Report mailed on April 4, 2005, for PCT application no. PCT//US04/21063 filed on June 29, 2004, 2 pages				
	32.	BLACK, G.E. et al. (January 2001) "Labeling DNA with Stable Isotopes: Economical and Practical Considerations," <i>BioTechniques</i> 30:134-140				
	33.	HO, D.D. et al. (1995) "Rapid Turnover of Plasma Virions and CD4 Lymphocytes in HIV-1 Infection," <i>Nature</i> 373:123-126				
	34.	HSIEH, Elaine A. et al. (2004) "Dynamics of Keratinocytes in Vivo Using 2H2O Labeling: A Sensitive Marker of Epidermal Proliferation State," J Invest Dermatol, 123: 530-536				
	35.	MESSMER, Bradley T. et al. (Feb. 10, 2005) "In Vivo Measurements Document the Dynamic Cellular Kinetics of Chronic Lymphocytic Leukemia B Cells," J. Clin. Invest. doi:10.1172/JCl200523409				
	36.	PARK, S. S., et al. (1997) "Measurement of Small Intestinal Cell Turnover with [6,6, 2H2] Glucose," <i>Berkeley Scientific, Abstract</i> 1(2):41-43				
·	37.	NEESE, R. A. et al. (Nov. 2002) "Measurement in vivo of Proliferation Rates of Slow Turnover Cells by 2H2O Labeling of the Deoxyribose Moiety of DNA," PNAS, 99(24): 15345-15350				
	38.	SMITH, et al. (1983) "The Phosphogluconate Odixative Pathway," in Principles of Biochemistry, 7th edition, McGraw-Hill Book Company, pp. 417-423.				
	39.	WOLFE, R. (1990) "Isotopic Measurement of Glucose and Lactate Kinetics," <i>Ann. Med.</i> 22:163-170				

^{*}EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner		Date	
Signature		Considered	İ
4.3	 		

^{&#}x27;Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached.